Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Annual report

4886.TEDINET S100TOTO
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 96
MetricValuePeriodScopeSource row
Revenue¥62.8bn2023-04-01 → 2024-03-31Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31dCons.Net sales (5-year summary)
Operating income¥6.5bn2023-04-01 → 2024-03-31Cons.Operating income
Operating income¥5.1bn2022-04-01 → 2023-03-31Cons.Operating income
Ordinary income¥6.5bn2023-04-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥9.9bn2023-04-01 → 2024-03-31Cons.Income before income taxes
Profit before tax¥5.4bn2022-04-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss
Net income¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss
Total assets¥90.7bnat 2024-03-31Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥83.3bnat 2022-03-31dCons.Total assets (5-year summary)
Total liabilities¥28.8bnat 2024-03-31Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥61.9bnat 2024-03-31Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31dCons.Net assets
Cash and deposits¥13.7bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥16.7bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥3.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow¥1.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥266.512023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥2,186.1at 2024-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,928.14at 2023-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,734.8at 2022-03-31dCons.Net assets per share (5-year summary)
Equity ratio68.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31dCons.Equity to asset ratio (5-year summary)
ROE13.0%2023-04-01 → 2024-03-31Cons.Rate of return on equity (5-year summary)
ROE8.2%2022-04-01 → 2023-03-31Cons.Rate of return on equity (5-year summary)
ROE8.8%2021-04-01 → 2022-03-31dCons.Rate of return on equity (5-year summary)
Employees762at 2024-03-31Cons.Number of employees
Employees747at 2023-03-31Cons.Number of employees
Employees777at 2022-03-31dCons.Number of employees
Revenue¥3.7bn2023-04-01 → 2024-03-31StandaloneOperating revenue1
Revenue¥1.7bn2022-04-01 → 2023-03-31StandaloneOperating revenue1
Revenue¥1.4bn2021-04-01 → 2022-03-31dStandaloneOperating revenue1 (5-year summary)
Operating income¥2.5bn2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥658m2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥2.5bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥603m2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥717m2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥2.5bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥603m2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥2.5bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥591m2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥682m2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Total assets¥43.2bnat 2024-03-31StandaloneAssets
Total assets¥41.6bnat 2023-03-31StandaloneAssets
Total assets¥41.3bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥565mat 2024-03-31StandaloneLiabilities
Total liabilities¥630mat 2023-03-31StandaloneLiabilities
Net assets / equity¥42.7bnat 2024-03-31StandaloneNet assets
Net assets / equity¥40.9bnat 2023-03-31StandaloneNet assets
Net assets / equity¥40.7bnat 2022-03-31dStandaloneNet assets
Cash and deposits¥2.2bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥1.1bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥87.12023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥20.952022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥23.792021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥402023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥162022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥152021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,506.47at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,447.55at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,443.94at 2022-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio98.7%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE5.9%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE1.5%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE1.7%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued30,563,199at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees75at 2024-03-31StandaloneNumber of employees
Employees79at 2023-03-31StandaloneNumber of employees
Employees74at 2022-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 55
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2024-03-3115 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2024-03-31¥226m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2024-03-31¥162m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2024-03-31¥64m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2024-03-31¥39m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2024-03-31−¥125m
Reconciling Itemsreconcilingdepreciation2023-04-01 → 2024-03-31¥201m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2024-03-31−¥64m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2024-03-31−¥64m
Reconciling Itemsreconcilingsegment assetsat 2024-03-31¥42.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥1.2bn
Animal Health Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥4m
Animal Health Businessreportable segmentemployeesat 2024-03-3134 pure
Animal Health Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥6.7bn
Animal Health Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥6.7bn
Animal Health Businessreportable segmentsegment assetsat 2024-03-31¥3.5bn
Animal Health Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥195m
Pharmaceutical Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥2.2bn
Pharmaceutical Businessreportable segmentemployeesat 2024-03-31627 pure
Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥56.0bn
Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥56.0bn
Pharmaceutical Businessreportable segmentsegment assetsat 2024-03-31¥45.0bn
Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥7.6bn
Total Of Reportable Segments And Otherssegment totaldepreciation2023-04-01 → 2024-03-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2024-03-31¥62.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2024-03-31¥62.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2024-03-31¥64m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2024-03-31¥48.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2024-03-31¥7.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2023-03-31¥298m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2023-03-31¥220m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2023-03-31¥77m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2023-03-31¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2023-03-31−¥6m
Reconciling Itemsreconcilingdepreciation2022-04-01 → 2023-03-31¥481m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2023-03-31−¥77m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2023-03-31−¥77m
Reconciling Itemsreconcilingsegment assetsat 2023-03-31¥43.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥1.1bn
Animal Health Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥4m
Animal Health Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥6.7bn
Animal Health Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥6.7bn
Animal Health Businessreportable segmentsegment assetsat 2023-03-31¥3.0bn
Animal Health Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥409m
Pharmaceutical Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥2.5bn
Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥53.6bn
Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥53.6bn
Pharmaceutical Businessreportable segmentsegment assetsat 2023-03-31¥40.1bn
Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥5.8bn
Total Of Reportable Segments And Otherssegment totaldepreciation2022-04-01 → 2023-03-31¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2023-03-31¥60.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2023-03-31¥60.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2023-03-31¥77m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2023-03-31¥43.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2023-03-31¥6.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,450
ItemContextValueUnit
Interest expenses noePrior1YearDuration50000000JPY
Interest expenses noeCurrentYearDuration40000000JPY
Equity in losses of affiliates noePrior1YearDuration19000000JPY
Equity in losses of affiliates noeCurrentYearDuration41000000JPY
Foreign exchange losses noePrior1YearDuration43000000JPY
Foreign exchange losses noeCurrentYearDuration51000000JPY
Loss on disposal of noncurrent assets noePrior1YearDuration52000000JPY
Loss on disposal of noncurrent assets noeCurrentYearDuration13000000JPY
Expenses of inactive non current assets noePrior1YearDuration53000000JPY
Expenses of inactive non current assets noeCurrentYearDuration91000000JPY
Rent expenses on real estates noePrior1YearDuration6000000JPY
Rent expenses on real estates noeCurrentYearDuration55000000JPY
Contribution of esop trust noePrior1YearDuration51000000JPY
Contribution of esop trust noeCurrentYearDuration－JPY
Other noePrior1YearDuration31000000JPY
Other noeCurrentYearDuration98000000JPY
Non operating expensesPrior1YearDuration308000000JPY
Non operating expensesCurrentYearDuration392000000JPY
Ordinary incomePrior1YearDuration5232000000JPY
Ordinary incomeCurrentYearDuration6522000000JPY
Gain on sales of investment securities eiPrior1YearDuration124000000JPY
Gain on sales of investment securities eiCurrentYearDuration3340000000JPY
Extraordinary incomePrior1YearDuration124000000JPY
Extraordinary incomeCurrentYearDuration3340000000JPY
Income before income taxesPrior1YearDuration5357000000JPY
Income before income taxesCurrentYearDuration9862000000JPY
Income taxes currentPrior1YearDuration1108000000JPY
Income taxes currentCurrentYearDuration3514000000JPY
Income taxes deferredPrior1YearDuration10000000JPY
Income taxes deferredCurrentYearDuration-1197000000JPY
Income taxesPrior1YearDuration1118000000JPY
Income taxesCurrentYearDuration2316000000JPY
Profit lossPrior1YearDuration4238000000JPY
Profit lossCurrentYearDuration7545000000JPY
Profit loss attributable to owners of parentPrior1YearDuration4238000000JPY
Profit loss attributable to owners of parentCurrentYearDuration7545000000JPY
Profit lossPrior1YearDuration4238000000JPY
Profit lossCurrentYearDuration7545000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YearDuration1371000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYearDuration202000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YearDuration144000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYearDuration362000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YearDuration229000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYearDuration16000000JPY
Other comprehensive incomePrior1YearDuration1745000000JPY
Other comprehensive incomeCurrentYearDuration581000000JPY
Comprehensive incomePrior1YearDuration5983000000JPY
Comprehensive incomeCurrentYearDuration8127000000JPY
Comprehensive income attributable to owners of the parentPrior1YearDuration5983000000JPY
Comprehensive income attributable to owners of the parentCurrentYearDuration8127000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
balance sheet identitynon_consolidated 2023-03-31pass rounding
balance sheet identitynon_consolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass